U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C17H23Cl2NO.C4H6O6.H2O
Molecular Weight 496.379
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TESOFENSINE TARTRATE MONOHYDRATE

SMILES

O.O[C@H]([C@@H](O)C(O)=O)C(O)=O.CCOC[C@H]1[C@H]2CC[C@@H](C[C@@H]1C3=CC=C(Cl)C(Cl)=C3)N2C

InChI

InChIKey=MLBOTABDHOAIGP-ZUVYWPKOSA-N
InChI=1S/C17H23Cl2NO.C4H6O6.H2O/c1-3-21-10-14-13(9-12-5-7-17(14)20(12)2)11-4-6-15(18)16(19)8-11;5-1(3(7)8)2(6)4(9)10;/h4,6,8,12-14,17H,3,5,7,9-10H2,1-2H3;1-2,5-6H,(H,7,8)(H,9,10);1H2/t12-,13+,14+,17+;1-,2-;/m01./s1

HIDE SMILES / InChI
Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C4H6O6
Molecular Weight 150.0868
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED
Molecular Formula C17H23Cl2NO
Molecular Weight 328.277
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Tesofensine (also known as NS-2330) is a novel triple monoamine reuptake inhibitor with intrinsic inhibitory activity on norepinephrine (NE), serotonin (5-HT), and dopamine (DA) transporter function. It was development by NeuroSearch as a potential therapy for Alzheimer's disease (AD) and Parkinson's diseases, but these efforts have been discontinued. In phase II clinical trials with tesofensine in obese individuals, dose-related reductions in body weight, body fat and waist circumference, as well as improvements in other obesity-related endocrine factors were observed and the FDA recently endorsed the phase III trial program for this agent.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Blocker
555
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
Disc. AE: syncope, Vertigo...
Other AEs: Nausea, vomiting...
AEs leading to
discontinuation/dose reduction:
syncope (2%)
Vertigo (2%)
Vertigo2 (16%)
Hypervigilance (2%)
Mood altered (8%)
Pain of skin (2%)
Ear and labyrinth disorders (2%)
Other AEs:
Nausea (22.4%)
vomiting (4.1%)
Dry mouth (59.2%)
Toothache (4.1%)
Abdominal pain (12.2%)
Diarrhoea (18.4%)
Constipation (16.3%)
Faeces hard (10.2%)
Faecaloma (6.1%)
Insomnia (16.5%)
Dyssomnia (2%)
Hypervigilance (6.1%)
Dizziness (12.2%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
AEs

AEs

AESignificanceDosePopulation
Faeces hard 10.2%
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
Abdominal pain 12.2%
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
Dizziness 12.2%
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
Vertigo2 16%
Disc. AE
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
Constipation 16.3%
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
Insomnia 16.5%
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
Diarrhoea 18.4%
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
Dyssomnia 2%
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
Ear and labyrinth disorders 2%
Disc. AE
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
Hypervigilance 2%
Disc. AE
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
Pain of skin 2%
Disc. AE
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
Vertigo 2%
Disc. AE
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
syncope 2%
Disc. AE
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
Nausea 22.4%
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
Toothache 4.1%
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
vomiting 4.1%
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
Dry mouth 59.2%
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
Faecaloma 6.1%
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
Hypervigilance 6.1%
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
Mood altered 8%
Disc. AE
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/18950853/
PubMed

PubMed

TitleDatePubMed
New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier?
2010-11
The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men.
2010-11
[Recent progress and novel perspectives on obesity pharmacotherapy].
2010-08
Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users.
2010-07
The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant.
2010-06-25
Effect of centchroman coadministration on the pharmacokinetics of metformin in rats.
2010-06
Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat.
2010-06
Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine.
2010-06
Pharmacological management of appetite expression in obesity.
2010-05
Tackling obesity: new therapeutic agents for assisted weight loss.
2010-04-26
[Drug treatment of obesity--current situation and perspectives].
2010
Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole.
2010
[The effect of tesofensine on body weight and body composition in obese subjects--secondary publication].
2009-10-05
[Is there a future for medical treatment of obesity?].
2009-10-05
Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity.
2009-10
Gateways to clinical trials.
2009-09
Polymorphisms of serotonin receptor 2A and 2C genes and COMT in relation to obesity and type 2 diabetes.
2009-08-19
Tesofensine--a novel potent weight loss medicine. Evaluation of: Astrup A, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1906-13.
2009-07
Tesofensine and weight loss.
2009-02-28
Tesofensine and weight loss.
2009-02-28
A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam.
2009
Triple reuptake inhibitors: the next generation of antidepressants.
2008-12
Is new hope on the horizon for obesity?
2008-11-29
Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.
2008-11-29
Gateways to clinical trials.
2008-10
Triple reuptake inhibitors: a premise and promise.
2008-09
Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease.
2008-06
Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study.
2008-05
Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach.
2008-01
Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease.
2007-07
Gateways to clinical trials.
2007-03-09
Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease.
2007-02-15
Expression of brain derived neurotrophic factor, activity-regulated cytoskeleton protein mRNA, and enhancement of adult hippocampal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine re-uptake inhibitor tesofensine.
2007-01-26
Chronic fluoxetine treatment induces brain region-specific upregulation of genes associated with BDNF-induced long-term potentiation.
2007
Patents

Patents

06288079
4
06395748
6
JP2011529923A
42

Sample Use Guides

In Vivo Use Guide
tesofensine 0.5 mg may cause almost double the weight loss
Route of Administration: Oral
In Vitro Use Guide
In vitro investigations resulted in IC50 values for tesofensine of 11 and 1.7 nM for the [3 H]5-HT and [3 H]noradrenaline uptake, respectively.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:12:33 GMT 2025
Edited
by admin
on Mon Mar 31 18:12:33 GMT 2025
Record UNII
1HJG8C744G
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TESOFENSINE TARTRATE MONOHYDRATE
Common Name English
NS-2330 TARTRATE MONOHYDRATE
Preferred Name English
Code System Code Type Description
FDA UNII
1HJG8C744G
Created by admin on Mon Mar 31 18:12:33 GMT 2025 , Edited by admin on Mon Mar 31 18:12:33 GMT 2025
PRIMARY
PUBCHEM
76964625
Created by admin on Mon Mar 31 18:12:33 GMT 2025 , Edited by admin on Mon Mar 31 18:12:33 GMT 2025
PRIMARY
Related Record Type Details
Structure of TESOFENSINE TARTRATE
ANHYDROUS->SOLVATE
Structure of TESOFENSINE
PARENT -> SALT/SOLVATE
Structure of Tartaric Acid
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of TESOFENSINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966